Crystalline pharmaceutical and methods of preparation and use thereof
View Patent ↗Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
1. A method of treating dry eye disease in a subject in need of such treatment, the method comprising administering to the subject an effective amount of a composition comprising an isolated compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein said compound comprises a purity of greater than about 90%.
2. The method of claim 1 , wherein said compound has a purity of greater than about 98%.
3. The method of claim 1 , wherein said compound comprises at least about 95% of an S-enantiomer.
4. The composition of claim 1 , wherein said compound is a sodium salt.